Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous Close | 63.77 |
| Open | 63.49 |
| Bid | 62.94 x 1300 |
| Ask | 62.86 x 1300 |
| Day's Range | 62.30 - 63.78 |
| 52 Week Range | 57.17 - 74.12 |
| Volume | |
| Avg. Volume | 6,694,436 |
| Market Cap | 78.787B |
| Beta (5Y Monthly) | 0.33 |
| PE Ratio (TTM) | 19.22 |
| EPS (TTM) | 3.27 |
| Earnings Date | Oct 26, 2022 - Oct 31, 2022 |
| Forward Dividend & Yield | 2.92 (4.65%) |
| Ex-Dividend Date | Sept 14, 2022 |
| 1y Target Est | 70.78 |
- Simply Wall St.
Institutional owners may take dramatic actions as Gilead Sciences, Inc.'s (NASDAQ:GILD) recent 4.2% drop adds to one-year losses
A look at the shareholders of Gilead Sciences, Inc. ( NASDAQ:GILD ) can tell us which group is most powerful. We can...
- ACCESSWIRE
4 Questions With Dr. Javier Cortes: The Importance of Scientific Exchange To Advance Breast Cancer
NORTHAMPTON, MA / ACCESSWIRE / September 23, 2022 / Gilead Sciences For Dr. Javier Cortes, being a breast cancer researcher isn't just a profession - it's a calling. As the head of the International Breast Cancer Center (IBCC) in Madrid and Barcelona, ...
- Motley Fool
Got $1,000? 2 Stocks That Could Be Bargain Buys For 2022 and Beyond
Let's look at two biotech stocks that look attractive at current levels: AbbVie (NYSE: ABBV) and Gilead Sciences (NASDAQ: GILD). AbbVie is one of the largest pharmaceutical companies around. Like other drugmakers, AbbVie benefits from the fact that doctors do not stop prescribing lifesaving drugs even during challenging economic times, nor do patients stop taking them.
© 2022 Yahoo. All rights reserved.
